🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 58 of 757 · Phase 3 first, then by program name

  1. Fluticasone/ Formoterol

    China SXT Pharmaceuticals

    Asthma

    phase 3 small molecule active

    1 trial

  2. Fluzoparib

    China SXT Pharmaceuticals

    Breast Cancer Metastatic

    phase 3 small molecule active

    2 trials

  3. Fordadistrogene Movaparvovec, ECULIZUMAB, Placebo for PF-06939926

    Pfizer Ireland Pharmaceuticals Unlimited Company

    DUCHENNE MUSCULAR DYSTROPHY (DMD)

    phase 3 small molecule active

    1 trial

  4. ForeCYTE Breast Aspirator

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer, Preneoplastic Conditions, BRCA

    phase 3 other terminated

    1 trial

  5. Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  6. Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. Forxiga 10 mg film-coated tablets, Baxdrostat Placebo, Baxdrostat, Baxdrostat, Baxdrostat

    AstraZeneca AB

    Prevention of Heart failure

    phase 3 small molecule active

    1 trial

  8. Fosaprepitant

    First Tracks Biotherapeutics

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix

    Pharma Mar S.A.

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial

  10. Fosmetpantotenate

    Travere Therapeutics

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule terminated

    1 trial

  11. Fosrenol (Lanthanum Carbonate)

    Takeda Pharmaceuticals International AG

    Chronic Kidney Disease, Stage 5

    phase 3 small molecule completed

    1 trial

  12. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Covid19

    phase 3 small molecule completed

    1 trial

  13. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Immune Thrombocytopenic Purpura

    phase 3 small molecule completed

    3 trials

  14. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    2 trials

  15. Fp MDPI

    Teva Pharma GmbH

    Persistent Asthma

    phase 3 small molecule completed

    1 trial

  16. Fp/ABS

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule active

    1 trial

  17. Fremanezumab

    Teva Pharma GmbH

    Episodic Cluster Headache

    phase 3 small molecule terminated

    1 trial

  18. Fremanezumab

    Teva Pharma GmbH

    Chronic Cluster Headache

    phase 3 small molecule terminated

    1 trial

  19. Fremanezumab

    Teva Pharma GmbH

    Migraine Prophylaxis

    phase 3 small molecule completed

    1 trial

  20. Fremanezumab

    Teva Pharma GmbH

    Cluster Headache

    phase 3 small molecule terminated

    1 trial

  21. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  22. Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  23. Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém

    Pharma Mar S.A.

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

  24. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources